“Results from Part 1 Safety Run-in Period of a 2-Part, Phase 2, Multicenter, Open-Label, Proof-of-Concept Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of VP-315 in Subjects With Basal Cell Carcinoma”. 2023. SKIN The Journal of Cutaneous Medicine 7 (6): s260. https://doi.org/10.25251/skin.7.supp.260.